...Details were not disclosed. Shionogi has rights to pirfenidone from Marnac Inc. (Dallas, Texas) and KDL GmbH...

...Pharma FDA approves Apriso mesalamine for maintenance of remission of ulcerative colitis (UC) Shionogi/InterMune (NASDAQ:ITMN)/Marnac/ KDL GmbH...

...p38 mitogen-activated protein (MAP) kinase inhibitor in Japan, South Korea and Taiwan from Marnac and KDL GmbH...

...protein (MAP) kinase inhibitor in Japan, South Korea and Taiwan from Marnac (Dallas, Texas) and KDL...

...p38 mitogen-activated protein (MAP) kinase inhibitor in IPF in January 2009. Last year, Marnac and KDL GmbH...

...2Q08 Intercytex (LSE:ICX) ICX-PRO Stimulate repair in persistent chronic wounds Submit BLA 2H08 InterMune (NASDAQ:ITMN)/ Marnac/Shionogi/KDL...

...$28 from $38 after ITMN bought out its license for pirfenidone from Marnac and co-licensor KDL GmbH...

...Marnac and KDL sold worldwide rights to patents covering pirfenidone to ITMN for $13.5 million up...
...compound for fibrotic diseases in Japan, South Korea and Taiwan. InterMune Inc. (ITMN), Brisbane, Calif. KDL GmbH...

...72 weeks from 60 weeks. Shionogi has Japanese rights to the compound from Marnac and KDL GmbH...

...has Japanese rights to the oral p38 mitogen-activated protein (MAP) kinase inhibitor from Marnac and KDL GmbH...